Drew Rowan, MD
Family Medicine · Coatesville, PANPI 1285079384
Payments from drug & device makers
Across 102 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$213
- AstraZeneca$210
- AbbVie$182
- Pfizer$121
- Johnson & Johnson$106
- Merck$93
- plus $825 from 20 others
What the payments were for
- Food & beverage$1,751100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $213 |
| AstraZeneca | 14 | $210 |
| AbbVie | 11 | $182 |
| Pfizer | 8 | $121 |
| Johnson & Johnson(2 entities) | 6 | $106 |
| Merck | 6 | $93 |
| Boehringer Ingelheim | 5 | $88 |
| Amarin Pharma, Inc. | 5 | $88 |
| Lilly USA, LLC | 6 | $86 |
| GSK | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Astellas Pharma US Inc | 2 | $51 |
| Abbott | 2 | $46 |
| Sage Therapeutics, LLC | 1 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Amgen | 2 | $34 |
| Lundbeck LLC | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Novartis | 1 | $14 |
How this compares
$1,751 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 45 | $64,657 |
| OzempicSemaglutide | 28 | $48,268 |
| EliquisApixaban | 29 | $46,896 |
| XareltoRivaroxaban | 40 | $35,019 |
| JanuviaSitagliptin Phosphate | 23 | $34,372 |
| TrulicityDulaglutide | 28 | $32,649 |
| MounjaroTirzepatide | 20 | $20,493 |
| VraylarCariprazine Hcl | 13 | $17,388 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $16,418 |
| LinzessLinaclotide | 24 | $13,576 |
| MyrbetriqMirabegron | 21 | $11,343 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $8,752 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,882 |
| Dexlansoprazole DrDexlansoprazole | 20 | $5,281 |
| Atorvastatin Calcium | 468 | $4,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $88 | $64,65745 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $86 | $53,14248 claims |
| Novo NordiskOzempic | $213 | $48,26828 claims |
| PfizerEliquis | $121 | $46,89629 claims |
| Johnson & JohnsonXarelto | $106 | $35,01940 claims |
| MerckJanuvia | $93 | $34,37223 claims |
| AbbVieVraylar, Linzess, Synthroid | $182 | $33,13061 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $69 | $25,17032 claims |
| Astellas Pharma US IncMyrbetriq | $51 | $11,34321 claims |
| AstraZenecaSymbicort | $210 | $5,88218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Coatesville
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.